MultiTEP T-helper cell epitope platform (MultiTEP)

The MultiTEP platform is a recombinant protein-based vaccine technology designed to enhance the immunogenicity of vaccines targeting self-proteins, particularly in the context of neurodegenerative diseases (Davtyan et al., 2014, J Alzheimers Dis). It consists of a string of twelve universal T-helper (Th) cell epitopes derived from various pathogens, including tetanus toxin, diphtheria toxin, hepatitis B virus, and influenza virus (Ghochikyan et al., 2014, Sci Rep). These epitopes are selected for their ability to bind to a wide range of human leukocyte antigen (HLA) class II alleles, ensuring broad coverage across genetically diverse human populations (Nuravax Inc., 2024). By leveraging existing memory Th cells generated through prior infections or routine vaccinations, the MultiTEP platform provides potent help to B cells, facilitating the production of high titers of antibodies against the specific pathological antigen, such as Amyloid-beta or Tau, linked to the platform (Hovakimyan et al., 2023, Alzheimers Res Ther). This approach bypasses the need for activating potentially harmful auto-reactive T cells, thereby improving the safety profile of active immunotherapy for chronic conditions like Alzheimer's disease (Agadjanyan et al., 2015, J Alzheimers Dis).

Other names

Multiple T-helper cell epitopesMultiTEP vaccine platformMultiTEP carrierMultiTEP technology

Activation of universal memory T-helper cells to provide B-cell help for the production of high-affinity antibodies against co-delivered pathological antigens.